Camrelizumab combined with rivoceranib and TACE in the perioperative treatment of hepatocellular carcinoma: A randomized, open-label multicenter trial.

• DOI: 10.1200/jco.2025.43.16_suppl.e16279
• Publication Date: 2025-05-28T15:21:57Z
• Authors: Yongxiang Xia; Xiaofeng Wu; Aihua Yao; Xiaofeng Qian; Xinzheng Dai; Feng Zhang; Ke Wang; Chuanyong Zhang; Liyong Pu; Donghua Li; Ping Wang; Feng Cheng; Jie Zhao; Hui Zhang; Weiwei Tang; Yongxiang Zhan; Jinxue Zhou; Bin Zhang; Xiangcheng Li; Xuehao Wang
• Keywords: Open label

e16279 Background: The high recurrence rate following resection presents a significant challenge to the survival of patients with resectable hepatocellular carcinoma (HCC). Therefore, it is imperative develop novel and effective therapeutic interventions reduce improve prognosis HCC. This study aims evaluate efficacy safety camrelizumab combined rivoceranib TACE as perioperative treatment regimen in Methods: In this multicenter, randomized clinical trial, eligible HCC (CNLC stages Ib-IIIa) were randomly assigned 1:1 ratio either or control group. Patients group received one cycle TACE, followed by 2 cycles (200 mg Q2W) (250 QD), subsequently proceeded surgery. At least six sequential therapy Q3W) plus QD) was performed postoperatively.Patients surgical at QD). primary endpoint 2-year event-free rate. Secondary endpoints major pathological response (MPR) (defined ≤10% viable tumor cells bed), pathologic complete (pCR), disease-free (DFS), overall (OS), safety. Results: From March 2023 November 2024, 60 enrolled (31 patients) (29 median age subjects years (range: 31-76). Among them, 43 (71.7%) had hepatitis B virus (HBV) infection. group, 28 neoadjuvant therapy. Of these, 24 completed two preoperative underwent planned resection. Surgery canceled 4 patients: refused procedure, disease progression. MPR rates ITT population 22.6% (7/31). who 29.2% (7/24). Grade ≥3 treatment-related adverse events (TRAEs) occurred 5.9% 10.2% most common TRAEs occuring included platelet count decreased (22.5%), aspartate aminotransferase increased (19.3%) , neutrophil (14.7%). Conclusions: combination camrelizumab, rivoceranib, demonstrates both tolerability Preoperative has demonstrated promising response. However, due short follow-up duration, further research required determine whether can effectively long-term outcomes. Clinical trial information: NCT05613478 .